Discussion
NSCLC, lung adenocarcinoma
LUNG ADENOCARCINOMA, RECRUITMENT, NSCLC
This open-label, phase I trial builds on the existing evidence supporting the use of weekly docetaxel. The trial was terminated prematurely due to recruitment challenges relating to the approval of immunotherapies as a second-line treatment option in NSCLC after the trial was initiated [Our study adds to the existing evidence by indicating that nintedanib plus weekly docetaxel has a manageable safety profile [This study builds on the findings of the phase IIb SENECA trial of nintedanib after first-line chemotherapy in NSCLC. The SENECA trial evaluated nintedanib 200 mg BID in combination with a reduced dose of docetaxel (33 mg/mIn conclusion, this study provides further evidence that the combination of nintedanib plus weekly docetaxel is well tolerated in patients with locally advanced or metastatic lung adenocarcinoma who progressed on first-line platinum-based chemotherapy, with no apparent loss of docetaxel efficacy. Since the initiation of this trial, immunochemotherapy (or immunotherapy alone) has replaced chemotherapy as standard first-line treatment for patients with NSCLC lacking actionable mutations, based on seminal trials such as KEYNOTE 189 [